Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly P A
INSERM Unité 344-Endocrinologie Moléculaire, Faculté de Médecine Necker, Paris, France.
Endocr Rev. 1998 Jun;19(3):225-68. doi: 10.1210/edrv.19.3.0334.
PRL is an anterior pituitary hormone that, along with GH and PLs, forms a family of hormones that probably resulted from the duplication of an ancestral gene. The PRLR is also a member of a larger family, known as the cytokine class-1 receptor superfamily, which currently has more than 20 different members. PRLRs or binding sites are widely distributed throughout the body. In fact, it is difficult to find a tissue that does not express any PRLR mRNA or protein. In agreement with this wide distribution of receptors is the fact that now more than 300 separate actions of PRL have been reported in various vertebrates, including effects on water and salt balance, growth and development, endocrinology and metabolism, brain and behavior, reproduction, and immune regulation and protection. Clearly, a large proportion of these actions are directly or indirectly associated with the process of reproduction, including many behavioral effects. PRL is also becoming well known as an important regulator of immune function. A number of disease states, including the growth of different forms of cancer as well as various autoimmune diseases, appear to be related to an overproduction of PRL, which may act in an endocrine, autocrine, or paracrine manner, or via an increased sensitivity to the hormone. The first step in the mechanism of action of PRL is the binding to a cell surface receptor. The ligand binds in a two-step process in which site 1 on PRL binds to one receptor molecule, after which a second receptor molecule binds to site 2 on the hormone, forming a homodimer consisting of one molecule of PRL and two molecules of receptor. The PRLR contains no intrinsic tyrosine kinase cytoplasmic domain but associates with a cytoplasmic tyrosine kinase, JAK2. Dimerization of the receptor induces tyrosine phosphorylation and activation of the JAK kinase followed by phosphorylation of the receptor. Other receptor-associated kinases of the Src family have also been shown to be activated by PRL. One major pathway of signaling involves phosphorylation of cytoplasmic State proteins, which themselves dimerize and translocate to nucleus and bind to specific promoter elements on PRL-responsive genes. In addition, the Ras/Raf/MAP kinase pathway is also activated by PRL and may be involved in the proliferative effects of the hormone. Finally, a number of other potential mediators have been identified, including IRS-1, PI-3 kinase, SHP-2, PLC gamma, PKC, and intracellular Ca2+. The technique of gene targeting in mice has been used to develop the first experimental model in which the effect of the complete absence of any lactogen or PRL-mediated effects can be studied. Heterozygous (+/-) females show almost complete failure to lactate after the first, but not subsequent, pregnancies. Homozygous (-/-) females are infertile due to multiple reproductive abnormalities, including ovulation of premeiotic oocytes, reduced fertilization of oocytes, reduced preimplantation oocyte development, lack of embryo implantation, and the absence of pseudopregnancy. Twenty per cent of the homozygous males showed delayed fertility. Other phenotypes, including effects on the immune system and bone, are currently being examined. It is clear that there are multiple actions associated with PRL. It will be important to correlate known effects with local production of PRL to differentiate classic endocrine from autocrine/paracrine effects. The fact that extrapituitary PRL can, under some circumstances, compensate for pituitary PRL raises the interesting possibility that there may be effects of PRL other than those originally observed in hypophysectomized rats. The PRLR knockout mouse model should be an interesting system by which to look for effects activated only by PRL or other lactogenic hormones. On the other hand, many of the effects reported in this review may be shared with other hormones, cytokines, or growth factors and thus will be more difficult to study. (ABSTRACT TRUNCATED)
催乳素是一种垂体前叶激素,它与生长激素和胎盘催乳素一起,构成了一个可能源于祖先基因复制的激素家族。催乳素受体也是一个更大的家族的成员,即细胞因子1类受体超家族,目前该家族有20多个不同成员。催乳素受体或结合位点广泛分布于全身。事实上,很难找到一个不表达任何催乳素受体mRNA或蛋白质的组织。与这种广泛分布的受体相一致的是,现在已经报道了催乳素在各种脊椎动物中有300多种不同的作用,包括对水盐平衡、生长发育、内分泌和代谢、脑和行为、生殖以及免疫调节和保护的影响。显然,这些作用中有很大一部分直接或间接与生殖过程相关,包括许多行为效应。催乳素作为免疫功能的重要调节因子也越来越为人所知。许多疾病状态,包括不同形式癌症的生长以及各种自身免疫性疾病,似乎都与催乳素的过度产生有关,催乳素可能以内分泌、自分泌或旁分泌的方式起作用,或者通过对该激素的敏感性增加起作用。催乳素作用机制的第一步是与细胞表面受体结合。配体以两步过程结合,其中催乳素上的位点1与一个受体分子结合,之后第二个受体分子与激素上的位点2结合,形成由一个催乳素分子和两个受体分子组成的同二聚体。催乳素受体不包含内在的酪氨酸激酶胞质结构域,但与一种胞质酪氨酸激酶JAK2相关联。受体的二聚化诱导酪氨酸磷酸化和JAK激酶的激活,随后是受体的磷酸化。Src家族的其他受体相关激酶也已被证明可被催乳素激活。一条主要的信号通路涉及胞质状态蛋白的磷酸化,这些蛋白自身二聚化并转运到细胞核,与催乳素反应基因上的特定启动子元件结合。此外,Ras/Raf/MAP激酶通路也被催乳素激活,并可能参与该激素的增殖作用。最后,已经鉴定出许多其他潜在的介质,包括胰岛素受体底物-1、磷脂酰肌醇-3激酶、含Src同源2结构域蛋白-2、磷脂酶Cγ、蛋白激酶C和细胞内钙离子。小鼠基因靶向技术已被用于建立第一个实验模型,在该模型中可以研究完全缺乏任何催乳素或催乳素介导的效应。杂合子(+/-)雌性在第一次怀孕后几乎完全无法泌乳,但后续怀孕不受影响。纯合子(-/-)雌性由于多种生殖异常而不育,包括减数分裂前卵母细胞的排卵、卵母细胞受精减少、植入前卵母细胞发育减少、胚胎植入缺乏以及假孕的缺失。20%的纯合子雄性表现出生育延迟。目前正在研究其他表型,包括对免疫系统和骨骼的影响。显然,催乳素存在多种作用。将已知效应与催乳素的局部产生相关联,以区分经典内分泌效应和自分泌/旁分泌效应将很重要。垂体外催乳素在某些情况下可以补偿垂体催乳素这一事实,提出了一个有趣的可能性,即催乳素可能存在除最初在垂体切除大鼠中观察到的效应之外的其他效应。催乳素受体基因敲除小鼠模型应该是一个有趣的系统,通过它可以寻找仅由催乳素或其他催乳激素激活的效应。另一方面,本综述中报道的许多效应可能与其他激素、细胞因子或生长因子共有,因此将更难研究。